Oruka Therapeutics heads into its May 20 earnings call with one of the most aggressive short-interest buildups seen in the small-cap biotech space this year — and a Street that, for now, is pointing firmly in the opposite direction.
The short positioning shift has been the defining story of the past six weeks. Short interest climbed from roughly 7.4% of the free float in early April to nearly 17% by May 12 — more than doubling in six weeks. The weekly move alone was striking: SI jumped 29% over the past week, now representing close to 8.5 million shares. On a trailing month, the build is +125%. This is not a stock where shorts are nibbling at the edges.
Despite that accumulation, the lending market itself remains surprisingly relaxed. Cost to borrow has eased to around 0.48% APR — near the low end of a range that peaked above 0.71% in early April. Availability is ample, meaning there is no squeeze pressure building in the borrow pool. At 37% utilization of available shares, the lending market is far from stressed; a year ago, utilization hit a high of 93.8%, which makes the current setup look relatively uncrowded from a mechanical squeeze perspective. Options traders have swung to a notably more bullish posture. The put/call ratio fell to 0.75 — well below its 20-day average of 1.23 — reversing a sustained period of defensive positioning that ran through most of April, when PCR readings were in the 1.5–2.3 range. The message from options: hedging demand has dropped sharply just as short interest climbs.
The divergence between rising short interest and a falling put/call ratio is the tension worth watching. Bulls have a clear case from the Street. Multiple analysts raised targets in late April, with Barclays lifting to $160 and BTIG moving to $151 — both meaningful step-ups from the $78 targets they held just weeks earlier. UBS moved to $100. The consensus mean price target of $138 compares to a current price of $64.65, implying the Street collectively sees around 113% upside. All recent analyst moves have been upgrades or target raises; there has been no downgrade action in the data. The bullish thesis rests on ORKA-001's early clinical results, a longer half-life versus established competitors, and a clean balance sheet following a recent public offering. The bear case centres on the dominant competitive position of Skyrizi in psoriasis, uncertainty around EVERLAST-B data timing, and questions about whether ORKA-001's dosing advantage translates to meaningful market share gains. The ORTEX short score of 70.8 — up from 64.7 at the start of May — reflects this tug-of-war, ranking in the bottom decile of the broader universe on short score.
On the ownership side, Fidelity's FMR is the largest holder at 12.1% of shares. BlackRock added over 1.3 million shares in the April reporting period, and State Street added 731,000. Vanguard added 677,000. The three large passive and active managers collectively adding to positions provides a degree of structural support to the float. On the insider side, the COO sold approximately $299,000 worth of stock on May 1 across multiple tranches, and the Chief Medical Officer liquidated a similar amount in mid-April. Neither transaction looks alarming in isolation — both are small relative to total float — and the net 90-day insider flow remains modestly positive at around $1.6 million in value.
The last two earnings prints produced large moves: +30.5% the day after the March 13 release and +16.2% the following session. Two earlier prints in late 2025 were negative on the day but recovered over the subsequent week. The stock closed at $64.65 on May 12, down 6.2% on the week even as the month is still showing an 8.5% gain. Close peer SMMT gained 8% on the week while EDIT fell 3.6% and ANNX was off 4.9%, suggesting broader small-cap biotech weakness contributed to ORKA's pull-back rather than company-specific selling pressure.
The next catalyst is May 20. Whether the short build is a fundamental view on ORKA-001 competitive risk or a pre-earnings hedge — and how that unwinds against a Street consensus that has been raising targets aggressively — is the question that defines the setup into next week's print.
See the live data behind this article on ORTEX.
Open ORKA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
